Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 146

Sort by

Sort Order Select

Journal Articles

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 592.

https://doi.org/10.1182/blood-2024-201056

Published: 2024

Journal Articles

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

J Erin Wiedmeier-Nutor, Surendra Dasari, Richard Kumaran Kandasamy, Kiran Manalaparthi, Laura Ann Bruins, Gregory Ahmann, Mariano Arribas, P. Leif Bergsagel, Akhilesh Pandey, Esteban Braggio, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2024-206239

Published: 2024

Journal Articles

The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration

Saurabh Zanwar, Joseph Novak, Michael D Howe, Moritz Binder, Wilson I. Gonsalves, Esteban Braggio, Vincent Rajkumar, Dragan Jevremovic, Surendra Dasari, Shaji Kumar

Blood (2024) 144 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2024-203350

Published: 2024

Journal Articles

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, J Erin Wiedmeier-Nutor, Vikas A. Gupta, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rodrigo Fonseca, Michael Durante, Shannon M Matulis, Tomas Jelinek, Ola Landgren, Constantine S Mitsiades, P. Leif Bergsagel, Esteban Braggio, Lawrence H. Boise, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 249.

https://doi.org/10.1182/blood-2024-204071

Published: 2024

Journal Articles

Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals

Blood (2024) 144 (Supplement 1): 397.

https://doi.org/10.1182/blood-2024-194932

Published: 2024

Journal Articles

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2024-205385

Published: 2024

Journal Articles

Cyclin D1 Induces Global Epigenetic and Transcriptional Changes in Multiple Myeloma with t(11;14)(q13;q32)

Huihuang Yan, Suganti Shivaram, Hongwei Tang, Hans Anderson, Shulan Tian, Michael D Howe, Abiola Bolarinwa, Cinthya Zepeda Mendoza, Stacey Lehman, Leif Bergsagel, Esteban Braggio, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 6822.

https://doi.org/10.1182/blood-2024-208503

Published: 2024

Journal Articles

Incidence and Prevalence of Chronic Lymphocytic Leukemia in the 7-County Region Around Mayo Clinic, Rochester, Minnesota

Bryan A. Vallejo, Sara Achenbach, Kari G. Rabe, Aaron D. Norman, Celine M. Vachon, James R. Cerhan, Esteban Braggio, Susan M. Schwager, Tait D. Shanafelt, Curtis A. Hanson, Sameer A. Parikh, Neil E. Kay, Timothy G. Call, Susan L. Slager

Blood (2024) 144 (Supplement 1): 6801.

https://doi.org/10.1182/blood-2024-209069

Published: 2024

Journal Articles

Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)

Blood (2024) 144 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2024-194925

Published: 2024

Journal Articles

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Blood (2024) 144 (Supplement 1): 6201.

https://doi.org/10.1182/blood-2024-205509

Published: 2024

Journal Articles

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Blood (2024) 144 (12): 1284–1289.

https://doi.org/10.1182/blood.2023023639

Published: 2024

Includes: Supplemental data

Journal Articles

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Salma B. Abdelbaky, Brian Giacopelli, Kari G. Rabe, Kyoko Yamaguchi, Yue-Zhong Wu, Huihuang Yan, Tait D. Shanafelt, Sameer A. Parikh, Wei Ding, Paul J. Hampel, Sochilt Brown, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Curtis A. Hanson, Alexander S. Parker, Esteban Braggio, Susan L. Slager, Christopher C. Oakes

Blood (2024) 143 (17): 1752–1757.

https://doi.org/10.1182/blood.2023022180

Published: 2024

Includes: Supplemental data

Journal Articles

Incidence of Richter Transformation in Patients with Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL): A Cohort Study Evaluating Different Therapeutic Eras

Blood (2023) 142 (Supplement 1): 3271.

https://doi.org/10.1182/blood-2023-185076

Published: 2023

Journal Articles

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Sinto Sebastian Chirackal, Taro Hitosugi, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2023-189785

Published: 2023

Journal Articles

Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2023) 142 (Supplement 1): 3276.

https://doi.org/10.1182/blood-2023-183007

Published: 2023

Journal Articles

High Deletion Burden Identified By Whole Genome Sequencing Is Associated with Enhanced Risk in del17p CLL Patients

Preeti Trisal, Esteban Braggio, Nicholas Stong, Kay L. Medina, Sameer A. Parikh, Daniel L. Van Dyke, Kari G. Rabe, Zhiquan Wang, C. Chris Huang, Anita K. Gandhi, Neil E. Kay

Blood (2023) 142 (Supplement 1): 6509.

https://doi.org/10.1182/blood-2023-173881

Published: 2023

Journal Articles

Outcomes of Patients with Small Lymphocytic Lymphoma (SLL) Receiving First Line Treatment

Blood (2023) 142 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2023-181866

Published: 2023

Journal Articles

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

Rosalie Griffin, Aswin Sekar, Sameer A. Parikh, Giulio Genovese, Dennis P. Robinson, Aaron D. Norman, Janet E. Olson, Kari G. Rabe, Nicholas J. Boddicker, Paul J. Hampel, Neil E. Kay, Timothy G. Call, James R. Cerhan, Esteban Braggio, Curtis A. Hanson, Caline M. Vachon, Tait D. Shanafelt, Benjamin L. Ebert, Susan L. Slager

Blood (2023) 142 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2023-184696

Published: 2023

Journal Articles

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

Blood (2023) 142 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2023-182874

Published: 2023

Journal Articles

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity

Rodrigo Fonseca, Yuan Xiao Zhu, P. Leif Bergsagel, Marta Chesi, Akhilesh Pandey, Kiran Mangalaparthi, Yi Chen, Felai Tan, Stephen P. Anthony, Yu Chen, Yue Shen, Bing Dai, Esteban Braggio, Rafael Fonseca

Blood (2022) 140 (Supplement 1): 7129–7130.

https://doi.org/10.1182/blood-2022-167372

Published: 2022

NARROW

Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Cyclin D1 Induces Global Epigenetic and Transcriptional Changes in Multiple Myeloma with t(11;14)(q13;q32)

Incidence and Prevalence of Chronic Lymphocytic Leukemia in the 7-County Region Around Mayo Clinic, Rochester, Minnesota

Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature

Incidence of Richter Transformation in Patients with Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL): A Cohort Study Evaluating Different Therapeutic Eras

Unraveling Antioxidative Metabolic Pathways in Multiple Myeloma: Augmenting IMiD Sensitivity through Intracellular Cysteine Biosynthesis Inhibition

Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL)

High Deletion Burden Identified By Whole Genome Sequencing Is Associated with Enhanced Risk in del17p CLL Patients

Outcomes of Patients with Small Lymphocytic Lymphoma (SLL) Receiving First Line Treatment

Mosaic Chromosomal Alterations and Monoclonal B-Cell Lymphocytosis: Relationship and Risk of Hematologic Malignancies

Genome-Wide DNA Methylation Analysis Reveals Epigenetic Influence on Intracellular and Cytokine Signaling Pathways in Waldenström Macroglobulinemia Compared to IgM-MGUS

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only